This unit presents methods to assess the immunosuppressive properties of immunoregulatory cells of myeloid origin, such as myeloid-derived suppressor cells (MDSCs), both in vitro and in vivo in mice, as well as in biological samples from cancer patients. These methods could be adapted to test the impact of different suppressive populations on T cell activation, proliferation, and cytotoxic activity; moreover, they could be useful to assess the influence exerted by genetic modifications, chemical inhibitors, and drugs on immune suppressive pathways C 2018 by John Wiley & Sons, Inc.
INTRODUCTION
MDSCs are immature myeloid cells with potent immune suppressive activity that are characterized by a pathological state of activation Gabrilovich et al., 2007) .
Two major subsets of MDSCs have been classified based on their phenotypic and morphological features: monocytic (M)-MDSCs and polymorphonuclear (PMN)-MDSCs. In mice, MDSCs described in the past as CD11b + and Gr-1 + cells (Bronte et al., 2000; Dolcetti et al., 2010) are now better identified as CD11b + Ly6C hi Ly6G -(M-MDSCs) and CD11b + Ly6C lo Ly6G + (PMN-MDSCs) De Sanctis, Bronte, & Ugel, 2016a; Dolcetti et al., 2010; Movahedi et al., 2008; Peranzoni et al., 2010) .
In cancer patients, the characterization of MDSCs is more complex, although it is currently accepted that three main subsets of circulating MDSCs exist, i.e., M-MDSCs and PMN-MDSCs, while a more immature population, whose counterpart in the mouse is not known, is defined as early-stage MDSCs (eMDSCs). Each of these subsets have been characterized by different combinations of myeloid markers and contain more than a single phenotype Damuzzo et al., 2015) . Moreover, a recent study demonstrated that human MDSCs, under different conditions, can express additional markers such as CD38, LOX-1, and PD-L1, highlighting their great plasticity and adding additional layers of complexity to MDSC characterization and targeting (Tcyganov, Mastio, Chen, & Gabrilovich, 2018) .
Basic Protocol 1 shows how to isolate MDSCs from spleens of tumor-bearing mice, and Basic Protocol 2 illustrates how to generate MDSCs from mouse bone marrow (BM) samples. MDSCs obtained using these protocols can be assessed for their ability to suppress T cell proliferation in response to antigen-specific activation (Basic Protocol 3) or following nonspecific stimulation (Basic Protocol 4). Basic Protocol 5 shows how to assess T cell cytotoxic effector function in response to antigen-specific activation, and therefore a Support Protocol describing the calculation of results is included. A method to evaluate in vivo-induced immune suppression in mice is also presented (Basic Protocol 6). Basic Protocol 7 indicates how to isolate circulating human CD14 + cells enriched in M-MDSCs. Basic Protocol 8 illustrates how to expand in vitro human bone marrow-derived MDSCs (BM-MDSC), and Basic Protocol 9 describes how to test these cells for their suppressive function on T cell proliferation.
PMN-MDSCs share the expression of the markers CD11b, CD15, (or CD66b + ) and CD33 with neutrophils, but differ in their buoyant density, since PMN-MDSCs can be isolated in low-density Ficoll-gradient fraction, while neutrophils are present in the high-density fraction. Thus, the addition of a specific marker is warranted to obtain an enrichment of PMN-MDSCs. In this regard, we demonstrated that CD124 is upregulated both in M-MDSCs and in PMN-MDSCs, although its presence only correlates with an immunosuppressive phenotype in M-MDSCs but not PMN-MDSCs of tumorbearing patients. However, the isolation of CD124-positive versus -negative cells is technically challenging, since the staining of this antigen has a low intensity and a unimodal expression, thus making the separation of a highly enriched CD124 + population difficult to achieve. More recently, lectin-type oxidized LDL receptor 1 (LOX-1) has been proposed as a marker to distinguish human neutrophils from PMN-MDSCs without the use of a density gradient (Condamine et al., 2016) .
All the in vitro protocols were optimized for microcultures in order to reduce the number of cells to be used. Figure 1 Gating strategy to isolate mouse MDSC using flow cytometric sorting. Cell suspension from tissues (spleen, blood, or tumor) of tumor-bearing mice or in vitro-differentiated BM cells were stained with the following mix: anti-Ly6C, anti-ly6G, anti-CD11b and live-dead probe. The figure illustrates isolation of the two main MDSC subsets derived by sequential steps: a morpho gate, a viability gate, a myeloid gate, and an MDSC gate. The procedure makes it possible to isolate M-MDSCs and PMN-MDSCs with a purity of ß80% to 90%. and the molecular analysis protocols. In Figure 1 , the gating strategy and an example of separation are presented.
For tumor models in which low percentages of CD11b + cells accumulate in the spleen, the purity of MDSCs obtained could be lower; titration of antibodies and reagents may help in obtaining better results. Moreover, a pre-enrichment step through immunomagnetic sorting using specific CD11b microbeads could be coupled with this protocol according to the manufacturer's instructions (see mouse and human CD11b MicroBeads, Miltenyi). This might improve the results, but it might also affect the viability and performance of the sorted cells.
This protocol could be applied to separate myeloid subsets in lymphoid organs other than spleen (i.e., bone marrow and lymph nodes) or from the tumor mass; however, an organ might present some peculiarities due to its structure (for example, it is necessary to digest the tumor to obtain a single-cell suspension) or function (for example, lymph nodes contain lower amounts of myeloid cells), which might limit either purity or viability of the recovered cell fractions.
Ly-6G -CD11b + . This protocol is still valid in cases in which a FACS sorter is not available and when highly pure populations are not required.
Materials
Spleens from BALB/c or C57BL/6 tumor-bearing mice (mice purchased from Jackson Laboratories) or in vitro-generated MDSCs (see Basic Protocol 2) RPMI containing 3% FBS (see recipe) Red cell ACK lysis buffer (Lonza) Dulbecco's phosphate-buffered saline (DPBS; Lonza BioWhittaker, cat. no. BE17-515Q), cold Fc-receptor (FcR) blocking reagent (clone 2.4G2, ThermoFisher) Sorting buffer (see recipe) fixable viability stain Fixable Viability Dye (ThermoFisher) Anti mouse-CD11b (ThermoFisher) Anti mouse-Ly6G (ThermoFisher) Anti mouse-Ly6C (ThermoFisher) Fetal bovine serum (FBS), heat inactivated RPMI containing 10% FBS (see recipe) 10-mm culture dish 2-ml syringe 15-and 50-ml conical tubes Centrifuge 100-μm nylon-mesh cell strainer (BD Biosciences) MoFlo Astrios cell sorter (Beckman Coulter) LSRII flow cytometer (BD Biosciences) FlowJo 7.6.5 Software (TreeStar) Additional reagents and equipment to harvest spleens from mice (see Reeves & Reeves, 1992) and to determine cell number using trypan blue dye exclusion (Strober, 2001) NOTE: All antibodies need to be titrated. When working with more than one spleen and different amounts of cells adapt reagent volume accordingly.
Process spleen(s)
1. Collect spleens of tumor-bearing mice (Reeves & Reeves, 1992) in a small volume of RPMI containing 3% FBS under sterile conditions. Take care to clean spleen from surrounding fibrous tissue.
2. Place spleen in a 10-mm culture dish with a small volume of RPMI containing 3% FBS and gently disaggregate using the plunger of a 2-ml syringe.
If more than one spleen has to be collected to perform more tests, spleens can be stored in a small volume of RPMI containing 3% FBS in a 50-ml conical tube on ice.
3. Add 5 ml of RPMI containing 3% FBS to cells and, pipetting gently, collect the cells in a 50-ml conical tube. Repeat steps 2 and 3 until the complete disaggregation of the spleen has been achieved.
4. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
The supernatant may be discarded by decantation or aspiration.
5. Lyse red blood cells by adding a volume of 5 ml (for each spleen) of red cell ACK lysis buffer to the pelleted cells, and incubate at room temperature for 4 min.
6. Add a volume of RPMI containing 3% FBS equal to at least five times the volume of lysis buffer added, and mix by gently pipetting up and down.
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Current Protocols in Immunology 7. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
8. Resuspend cell pellet in 10 ml/spleen of RPMI containing 3% FBS, filter through a cell strainer (or a single sheet of nylon mesh) placed on the top of a 50-ml tube, and collect the suspension.
Filtration can be helped by pre-hydrating the nylon mesh with a small volume of medium.
9. Properly dilute an aliquot of the single-cell suspension with trypan blue solution (Strober, 2001) and estimate the number of viable cells, avoiding red blood cell counts.
Trypan blue colors dead cells a faint blue, and these cells should not be taken into account. Red blood cells can be recognized as small cells with a round shape and a neat, thick perimeter.
Separation of PMN-MDSCs and M-MDSCs from splenocytes
An example of gating strategy for the sorting and results analyzed with FlowJo 7.6.5 Software is shown in Figure 1 .
10. Transfer 1 × 10 8 viable cells obtained from the spleens of tumor-bearing mice to a new 15-ml conical tube, and then add 8 to 10 ml of DPBS to wash the cells.
In the case of spleens coming from mice with completely unknown tumors, the proportion of myeloid cells should be evaluated before staining a large sample.
11. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
12. Add 10 ml of sorting buffer and wash cells by gently pipetting up and down.
13. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
These fractions can be used to assess their immunosuppressive activity either in vitro and in vivo.
14. Incubate samples with 10 μl Fc-receptor blocking reagent in 50 μl of sorting buffer at room temperature for 10 min.
15. Add the mixture of antibody, composed of Fixable Viability Dye (5 μl), anti-CD11b (10 μl), anti Ly6G (10 μl), and anti Ly6C (10 μl), to the tubes and incubate at 4°C for 20 min. Adjust the volume of staining mix to 100 μl with the sorting buffer. Specifically, for FACS analysis, cells are stained in 15-ml polypropylene tubes previously coated for at least 1 hr with heat-inactivated fetal bovine serum.
16. Wash twice with sorting buffer. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
17. After labeling, resuspend samples at the concentration of 30 × 10 6 cells/ml of sorting buffer and proceed with the FACS separation as outlined in Figure 1 .
18. Filter MDSCs through a 100-µm cell strainer and isolate through MoFlo Astrios.
Sorting should be performed with a 100-μm nozzle, setting the pressure, voltage, and cell rate as appropriate for the sorter.
19. Collect sorted M-MDSCs and PMN-MDSCs in two different 15-ml polypropylene tubes previously coated for at least 1 hr with heat-inactivated fetal bovine serum.
20. After the separation, wash and resuspend M-MDSCs and PMN-MDSCs in 10 ml of RPMI/10% FBS. Take an aliquot of the single-cell suspension, dilute it properly with trypan blue solution, and estimate the number of viable cells (Strober, 2001) . Another aliquot is checked for purity with the LSRII flow cytometer.
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Current Protocols in Immunology NOTE: All the procedures, including the sorting, are performed at 4°C, to avoid cell loss and adherence to the plastic.
These fractions can be stained to assess the presence and distribution of markers that were used to characterize mouse MDSCs (Table 1) .
BASIC PROTOCOL 2

MOUSE BM-MDSC GENERATION
This protocol is optimized to obtain bone marrow (BM)-derived MDSCs from mice as previously described . BM cells are cultured for 4 days in the presence of the recombinant mouse cytokines GM-CSF and IL-6. The final cultures will contain proportions of PMN-MDSCs, M-MDSCs, and macrophages. Additional reagents and equipment to harvest bone marrow from mice (Reeves & Reeves, 1992) and to determine cell number using trypan blue dye exclusion (Strober, 2001) Process bone marrow (BM) 1. Remove tibias and femurs from mice, and remove the muscle from the bones with scissors.
Materials
Take care to avoid hair contamination 2. Cut the extremity of the bones with pliers and scissors under sterile conditions.
3. Flush the medium inside the bones with a small volume of RPMI containing 3% FBS, gently injected with a 2-ml syringe with a 26-G needle. Collect flushed-out material in 50-ml conical tubes containing 5 ml of RPMI containing 3% FBS BM-MDSC generation 4. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
5. For two legs, lyse red blood cells by adding a volume of 5 ml of red blood cell lysis buffer to the pelleted cells, and incubate at room temperature for 4 min.
6. Add a volume of RPMI/3% FBS equal to at least five times the volume of lysis buffer added, and mix by gently pipetting up and down.
7. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
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Current Protocols in Immunology 8. Resuspend the cells obtained from two legs in 5 ml of RPMI containing 10% FBS and filter the suspension through a cell strainer.
The volume can be scaled to meet researchers' needs; extra medium volume can also be added to rinse the cell strainer, minimizing cell loss.
9. Take an aliquot of the single-cell suspension, dilute it properly with trypan blue solution, and estimate the number of viable cells (Strober, 2001) .
10. Adjust the concentration of the BM suspension to 1.5 × 10 6 cells/ml using RPMI/10% FBS.
11. Plate 1 ml (1.5 × 10 6 cells) of BM cells in each well of a 6-well plate, add 2 ml of RPMI/10% FBS in the presence of cytokines GM-CSF and IL-6, both at a final concentration of 40 ng/ml (per well), and place the culture in a 37°C, 5% CO 2 incubator for 4 days.
12. At day 4 of culture, to test the immunosuppressive properties of the cells, gently harvest BM-MDSCs with a Pasteur pipette. Wash dishes with DPBS containing 2 mM EDTA to detach and collect the remaining cells.
BASIC PROTOCOL 3
MEASURING MYELOID-INDUCED SUPPRESSION OF T CELL ANTIGEN-INDUCED PROLIFERATION IN VITRO BY CELL TRACE DILUTION
Immune suppression exerted by myeloid cells to the detriment of activated T cells can be measured in terms of inhibition of proliferation by evaluating dye dilution to trace multiple generations of proliferating lymphocytes.
Materials
Immunosuppressive cells, e.g., MDSCs (Basic Protocol 1 or 2) RPMI containing 10% FBS (see recipe) CD45. Additional reagents and equipment to prepare immunosuppressive cells (Basic Protocol 1 and 2), harvest spleens from mice (Reeves & Reeves, 1992) , and count viable cells by trypan blue exclusion (Strober, 2001) Day 0: Suppressive cell plating 1. Prepare MDSCs, according to Basic Protocol 1 or 2.
2. Wash cells twice in RPMI medium containing 10% FBS and resuspend in a suitable volume of RPMI containing 10% FBS.
3. Dilute an aliquot of suspension in trypan blue solution and determine viable cell concentration (Strober, 2001) .
4. Adjust cell concentration appropriately with RPMI/10% FBS. This assay requires a careful titration of the suppressive cells. The number of suppressor cells to add to each well will depend on the experimental plan. A good starting point could be to plate suppressor cells at 24% of the total cells in control cultures and serially dilute them by a factor of 2 until they represent ß1.5% of total cells. When organizing the distribution of samples, avoid using the outer wells, because these wells are more susceptible to evaporation. Outer wells can be filled with RPMI containing 3% FBS. Remember to fill at least three wells with RPMI/10% FBS without myeloid suppressor cells, to use as control cultures.
Plating splenocytes 6. Separately collect spleens from both CD45.1 and OT-1 mice (Reeves & Reeves, 1992) in a small volume of RPMI/3% FBS under sterile conditions.
Splenocytes from OT-1 mice need to be diluted with CD45.1 splenocytes to obtain a concentration of OVA-specific CD8 + T lymphocytes, which is 1% of total cultured cells (usually about 1:10 dilution is sufficient). Consequently, one spleen from OT-1 mice is sufficient for several microtiter plates. The percentage of specific OVA CD8 + T lymphocytes in total splenocytes can be determined before their use by cytometry staining with anti-CD8 and anti-V α 2 V β 5.1/5.2 mAbs to identify the specific T cell receptor (TCR).
7. Place spleens in a 10-mm culture dish with a small volume of RPMI/3% FBS, and gently disaggregate using the plunger of a 2-ml syringe.
8. Add 5 ml of RPMI/3% FBS to cells and collect the cells in a 50-ml conical tube by gently pipetting up and down. Repeat steps 7 and 8 until the spleen is completely disaggregated.
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Current Protocols in Immunology 9. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
10. Lyse red blood cells by adding about 5 ml of red cell lysis buffer for spleen, and incubate at room temperature for 4 min.
11. Add a quantity of RPMI/3% FBS equal to at least five volumes the quantity of lysis buffer applied, and mix by gently pipetting up and down.
It is very important to obtain a red blood cell-free suspension (see explanation in Commentary).
12. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
13. Resuspend cells in 1 ml of RPMI/10% FBS, and put on ice.
14. Wash both CD45.1 and OT-1 cells by adding 10 ml of RPMI/10% FBS.
15. Centrifuge the suspensions 6 min at 300 ×g, 4°C, and discard the supernatant.
16. Resuspend the cells in 2 ml/spleen of RPMI/10% FBS, and filter the suspension through a cell strainer.
17. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
18. Keep CD45.1 splenocytes on ice and wash OT-1 cells twice by adding 10 ml of ice-cold DPBS (4°C) and discarding the supernatant.
19. Adjust OT-1 splenocyte concentration to 20× 10 6 cells/ml concentration with room temperature DPBS and add an equal volume of DPBS containing CellTrace TM at the concentration of 5 μM (the final concentration of the suspension will be equal to half the concentration). Keep the suspension 5 min at 37°C in incubator and mix every minute.
20. Block the staining by adding an equal volume of FBS and keep at room temperature for 1 min. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
21. Wash cells twice in DPBS with 10% FBS and resuspend in 5 ml of RPMI.
22. Check the staining with CellTrace TM by flow cytometry.
When evaluating CellTrace incorporation, a control for autofluorescence value of unstained splenocytes should be included, to evaluate whether the difference in emission signals among unstained splenocytes and CellTrace + splenocytes is enough to be able to quantify extensive proliferation, which will bring a strong dilution of CellTrace signal. A successful staining is achieved when the histogram has a single, narrow peak. 
MEASURING MYELOID-INDUCED SUPPRESSION OF T CELL PROLIFERATION IN VITRO BY ANTI-CD3/ANTI-CD28 STIMULATION AND EVALUATION OF [ 3 H]THYMIDINE ([ 3 H]TdR) INCORPORATION
Proliferation of T cells can be induced by antigen-independent stimulation, and MDSCs can exert immune suppressive functions on these cells. The proliferative arrest of actively dividing cells can also be measured as a function of [ 3 H]TdR incorporation by T cells into their DNA. The method is extremely simple and provides a quantitative and relatively rapid analysis, which can be easily applied to complex experiments as large-scale screenings of drugs and treatments.
Materials
Dulbecco's phosphate-buffered saline (DPBS; Lonza BioWhittaker, cat. no.
BE17-515Q)
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Current Protocols in Immunology Anti-CD3 (2C11, ATCC) Anti-CD28 (clone 37.5, ATCC) Immunosuppressive (myeloid) cells, e.g., MDSCs (Basic Protocol Additional reagents and equipment to prepare immunosuppressive cells (Basic Protocol 1 or 2), harvest spleens from mice (Reeves & Reeves, 1992) , and count viable cells by trypan blue exclusion (Strober, 2001) Day 0: Culture plate coating 1. Prepare sufficient coating buffer: DPBS containing anti-CD3 (3 μg/ml final concentration) and anti-CD28 (2 μg/ml final concentration).
Antibody concentration may be optimized on the basis of stock and supplier; a suitable volume would be 11 ml of antibody solution per plate.
2. Fill 96-well flat-bottom microtiter plates with 100 μl/well anti-CD3 and anti-CD28containing DPBS with a multichannel pipettor; also fill an equal number of wells with 100 μl/well of DPBS without antibodies, for nonspecific proliferation measurement.
Also remember to fill extra wells for appropriate controls based on the experimental set up, e.g., suppressive cells only.
3. Incubate the plate overnight at 4°C.
Day 1: Cell plating
Plate immunosuppressive cells 4. Prepare myeloid (immunosuppressive) cells, e.g., MDSCs, according to Basic Protocol 1 or 2 or other strategies of enrichment.
Wash cells twice in RPMI containing 10% FBS and resuspend them in a suitable volume of RPMI/10% FBS.
The supernatant should be aspirated from the top; be careful to remove as much supernatant as possible without disturbing the cell pellet.
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Current Protocols in Immunology 6. Resuspend cells in a small volume of RPMI/10% FBS. Dilute an aliquot of suspension in trypan blue solution and determine viable cell concentration (Strober, 2001) .
Adjust cell concentration appropriately with RPMI/10% FBS.
The concentration depends upon the design of the experiment. A good range of MDSCs is 24% to 1.5% of the effector culture cellularity. If 0.6 × 10 6 effector cells are used, MDSC concentration can be adjusted to 1.44 × 10 6 /ml, so that 0.144 × 10 6 cells will be plated in 100 μl (24% of the effector cells).
8. Working under sterile conditions, empty 96-well microtiter plate (from step 3) by inverting it with a rapid movement.
Work under a laminar flow hood; a plastic basin wrapped with paper towels can be used to discard the coating buffer.
9. Fill every well with 200 μl of DPBS using a multichannel pipettor and empty the plate as in step 8. Repeat at least three times to wash extensively.
Fill the plate from the top of the well to avoid scratching the surface of the well, which might disturb the antibody coating.
10. Immediately plate suppressive cells in triplicate for specific and background proliferation in 100 μl of RPMI/10% FBS, and place the microtiter plate in a 37°C, 5% CO 2 incubator.
When organizing the distribution of samples, avoid using the outer wells, because these wells are more susceptible to evaporation. Outer wells can be filled with sterile medium. Remember to fill at least six wells with RPMI/10% FBS without suppressive cells; these wells will be used as control cultures for the determination of specific and nonspecific proliferation. Multiply these control wells for different treatments according to the experimental setup, e.g., different inhibitors and drugs to be tested.
Plate splenocytes
11. Collect spleens from C57BL/6 mice (Reeves & Reeves, 1992) in a small volume of RPMI containing 3% FBS under sterile conditions. Usually one spleen from an 8-week old-mouse is sufficient for one plate.
12. Place spleens in a 10-mm culture dish with a small volume of RPMI/3% FBS and gently disaggregate them using the plunger of a 2-ml syringe.
13. Add 5 ml of RPMI/3% FBS to cells and collect the cells in a 50-ml conical tube by gently pipetting. Repeat steps 12 and 13 until complete disaggregation of the spleen is achieved.
14. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
15. Lyse red blood cells by adding a volume of red cell ACK lysis buffer equal to the volume of the pelleted cells, and incubate at room temperature for 4 min.
16. Add a volume of RPMI/3% FBS equal to at least five times the volume of lysis buffer added, and mix by gently pipetting up and down.
17. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
18. Wash cells with 10 ml of RPMI/10% FBS.
19. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
20. Resuspend the cells in 2 ml of RPMI/10% FBS for each spleen and filter the suspension through a cell strainer.
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The volume can be scaled to meet researchers' needs; extra medium volume can also be added to rinse the cell strainer, preventing cell loss.
21.
Dilute an aliquot of the suspension in trypan blue solution and determine viable cell concentration (Strober, 2001) .
22. Adjust the concentration of the splenocyte suspension to 6 × 10 6 cells/ml with RPMI/10% FBS.
23. Immediately plate 100 μl of cell suspension onto the previously coated microtiter plate and incubate 3 days in the 37°C, 5% CO 2 incubator.
Pay attention to the cell distribution schema. Splenocytes will proliferate upon anti-CD3/anti-CD28 stimulation, and their proliferation will be inhibited by immunosuppressive cells; therefore, splenocytes should be distributed in previously anti-CD3/anti-CD28-coated wells, either with or without immunosuppressive cells, as test and reference wells, respectively. The proliferative behavior of MDSCs alone under these conditions should also be tested; therefore, MDSCs will be cultured with 100 μl of medium instead of effector cells.
[ 3 H]TdR should be added the third day after culture setup. It would be useful to check the cell culture daily in order to avoid medium exhaustion by excessive proliferation of cells (signaled by medium turning yellow) or initial cell death (granular, small cells instead of cell clumps). A wet Unifilter-96 GF/C is essential to obtain consistent results. 26 . Load the culture plate onto harvester and aspirate culture medium, collecting it in the "hot" radioactive waste tank.
27. Wash the plate five times with water and aspirate, collecting the supernatant in the "hot" radioactive waste tank. Repeat another five times using aspiration, collecting the supernatant in the "cold" radioactive waste tank.
28. Remove the culture plate from the harvester and replace it with a proper vessel filled with 96% ethanol. 
MEASURING MYELOID CELL-INDUCED SUPPRESSION OF T CELL CYTOTOXIC ACTIVITY IN VITRO: INHIBITION OF ANTIGEN-INDUCED CYTOTOXIC ACTIVITY OF T CELLS IN MICROCULTURES
Immune suppression exerted by myeloid cells to the detriment of activated T cells could also be measured in ways that can complement simply looking at the process of T cell expansion. Assessing the cytotoxic activity of CD8 + T cells, elicited by antigen-specific stimulation in vitro, will allow one to simultaneously assess both T cell abundance and functional effector state. 3. Immediately plate 100 μl of splenocyte suspension onto the previous microplate containing the immunosuppressive myeloid cells, and incubate for 5 days at 37°C, in the 5% CO 2 incubator.
Materials
Day 5: Target cell preparation 4. Collect EL4 in suspension cells from 75-cm 2 flasks in a 50-ml conical tube.
5. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
6. Resuspend the cells in 5 ml of 10% FBS in DPBS.
7. Dilute an aliquot of suspension in trypan blue solution and determine viable cell concentration (Strober, 2001) .
8. Aliquot 6 × 10 6 cells to two new 12-ml round-bottom tubes. Bring volume to 10 ml with 10% FBS in DPBS.
3 × 10 6 target cells are sufficient for at least 15 test plates. The quantity can be scaled when necessary; nevertheless, if more than 3 × 10 6 cells are needed, prepare different aliquots for the next steps.
9. Centrifuge the suspension 6 min at 300 × g, 4°C, and carefully discard the supernatant.
In this step, it is essential to eliminate as much supernatant as possible, in order to improve 51 Cr uptake by target cells.
10. Add 10 μl of undiluted FBS to both pellets.
If you decide to load a smaller number of cells, simply scale down FBS to obtain a 10% final concentration.
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Current Protocols in Immunology 11. Add 3 μl of OVA 257-264 peptide solution (10 mg/ml) to one of the two pellets (which will be the pulsed sample).
One pellet will not receive the peptide and will be used as control for nonspecific lysis. An EG7 cell line stably transfected to express the antigen OVA 257-264 is also available. These cells can also be used in the test to evaluate specific lysis.
12. Add 100 μl of 1 mCi/ml Na 51 CrO 4 to each tube and resuspend by gentle flicking.
Avoid the formation of bubbles.
13. Incubate 1 hr at 37°C, flicking the tube every 15 min. After 1 hr, wash the cells twice with RPMI containing 5% FBS, each time centrifuging the cells 10 min at 300 ×g, room temperature, removing the supernatant, and then resuspending the cells in 6 ml of RPMI/5% FBS. Determine viable cell concentration (Strober, 2001 ) and adjust to 0.02 × 10 6 cells/ml with RPMI/5% FBS.
During the 1-hr target incubation, proceed with the rest of the protocol (step 14 
Current Protocols in Immunology 19. Read LumaPlates in a TopCount scintillation counting device for 1 min/well. 51 Cr release due to lysis of target cells, measured by the TopCount device (see Basic Protocols 4 and 5), is expressed in counts per minute (cpm). TopCount makes it possible to set up reading protocols that can directly transform cpm values to percentage lysis, Solito et al.
Interpretation of results and calculation of lytic units
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Current Protocols in Immunology Results can be displayed in a line plot with the x axis representing culture dilution and the y axis representing percentage of lysis. Nonspecific lysis, if any was detected, could be subtracted from specific lysis point by point, or otherwise could be separately displayed.
Another way to represent the results, which is more straightforward and also makes it possible to average more experiments, is the calculation of Lytic Units (L.U.). This involves determination of the culture dilution necessary to obtain a given lysis percentage, usually 30% (L.U.30) or 50% (L.U.50). Such determinations could be achieved using any software allowing for nonlinear regression. Data are initially arranged in a table with two columns, the first indicating the amount of culture applied to the test (on the basis of the dilution), the other the percentage of specific lysis (see the two far-right columns of Table3). a Regarding the amount of culture (see equations in Support Protocol), we assume that the initial undiluted culture is 1 and that the second well, i.e., 1:3 of the initial culture, will be 0.33 and so on. If the reference culture, without suppressive cells, produces 30% lysis of target cells at the fifth dilution, 1 liter.U.30 of the culture will be 0.0123 (1/81) of the initial culture and the number of lytic units per culture will be 1/0.0123 = 81. At the same time, if a culture containing suppressive cells produces 30% lysis of target cells at the third dilution, 1 liter.U. 30 of this experimental culture will be 0.11 (1/9) of the initial culture and the number of lytic units per culture will be 1/0.11 = 9. The % L.U. 30 of the experimental culture in relation to the reference culture will therefore be 9/81 × 100 = 11%.
also be reported as absolute number of cells by counting the cells in the wells of culture plates before dilution.
BASIC PROTOCOL 6
MEASURING MYELOID CELL-DEPENDENT IN VIVO TOLERANCE BY ADOPTIVE TRANSFER
Immune suppression can also be studied in vivo, and the method is certainly more challenging than the in vitro setup. We previously presented a method ; also see previous version of this unit; doi: 10.1002/0471142735.im1417s91) to evaluate in vivo tolerance, by which normal healthy recipients were antigen stimulated and where MDSCs were adoptively transferred. This protocol permits the evaluation of tolerance in a situation of stimulation relatively free from the multiple variables present during either tumor growth or infectious diseases. Instead, the protocol reported below is extended to tumor-bearing mice where MDSCs are expanded in vivo, during tumor development, and the antigen is expressed by the tumor and is cross-presented to lymphocytes. The experiment must take into account at least three groups of animals: a group of tumor-free mice, one of tumor bearing mice and a group of vaccinated tumorbearing mice (Ugel et al., 2012) .
Materials
Dendritic cell (DC) preparation started 5 days before beginning this protocol ( Additional reagents and equipment for culturing dendritic cells Inaba et al., 2009) , harvesting spleens and other lymphoid organs from mice (Reeves & Reeves, 1992) , counting viable cells by trypan blue exclusion (Strober, 2001) , flow cytometry, injection of mice, to prepare immunosuppressive cells (Basic Protocol 1 or 2), euthanasia of mice (Reeves & Reeves, 1992) , and flow cytometric IFN-γ intracellular staining NOTE: 5 days before starting, set up a dendritic cell (DC) culture from mouse bone marrow as described in Inaba et al. (2009) , which will be used to vaccinate some groups of control mice.
Day 0
1. Collect EG7-OVA suspension cell line expressing OVA 257-264 from 75-cm 2 flasks in a 50-ml conical tube.
2. Gently pipet cells up and down with a 1-ml syringe and an 18-G needle.
3. Load the syringe and tap bubbles, change the needle to a 26-G size.
4. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
5.
Adjust EG7-OVA cell concentration to 10 × 10 6 cells/ml with serum-free RPMI and inject 100 µl (10 6 EG7 cells) subcutaneously into the flank of at least 5 mice per group of CD45.2 + C57BL/6 mice.
Also prepare uninjected controls.
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Current Protocols in Immunology Day 7 6. Collect spleens (Reeves & Reeves, 1992 ) from OT-1CD45.1 + mice in a small volume of RPMI containing 3% FBS under sterile conditions. 7. Place spleens in a 10-mm culture dish with a small volume of RPMI containing 3% FBS and gently disaggregate using the plunger of a 2-ml syringe.
8. Add 5 ml of RPMI containing 3% FBS to cells and collect the cells in a 50-ml conical tube by gently pipetting. Repeat until the spleen pulp is completely disaggregated.
9. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
10. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
11. Prepare CD8 + T cells by means of CD8α + T cell isolation kit from Miltenyi Biotech.
Alternatively, the whole spleen of the OT-1 CD41.1 + mouse could be used without any sorting. Determine abundance of CD8 + T cells by means of cytometric staining with anti-CD8 and anti-V α 2 V β 5.1/5.2, and collect an amount of total splenocytes that corresponds to 5× 10 6 CD8 + /V α 2 V β 5. 1/5.2 cells. 12. Wash enriched CD8 + T cells with at least 10 ml fresh serum-free RPMI 1640 medium twice, each time by centrifuging cells 6 min at 300 ×g, 4°C, and carefully discarding the supernatant.
13. Resuspend cells in a small volume of serum-free RPMI.
14. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
15. Adjust concentration to 25× 10 6 cells/ml with serum-free RPMI, place cells in a 50-ml conical tube, and put the tube on ice.
16. Warm CD45.2 + C57BL/6 mice under an infrared heat lamp for about 10 min.
Do not overheat mice, and do not exceed the correct number of mice per cage during warming steps.
17. Gently pipet cells up and down with a 1-ml syringe and a 18-G needle.
18. Load the syringe, change the needle to a 26-G size, and tap bubbles out. 
Current Protocols in Immunology Day 9 DC preparation 23. Gently remove cells from plate culture, washing wells several times with DPBS, and transfer cell suspension to a 50-ml conical tube.
24. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
25. Wash cell pellet by adding 10 ml serum-free RPMI; repeat steps 19 and 20 twice. 26 . Resuspend mature DC preparation in a small volume of serum-free RPMI.
27. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
28. Adjust concentration to 10 × 10 6 cells/ml with serum-free RPMI, place cells in a 50-ml conical tube, and put them on ice.
29. Check mature DC preparation by flow cytometry for CD11c expression and MHC II and CD80/CD86 up-regulation relative to immature DCs, as described in Inaba et al., (2009) .
Perform DC vaccination
This procedure is used as a control to make sure that the in vivo tolerance is maintained in the presence of further stimulation of CD8 + T lymphocytes.
30. Gently pipet mature DCs up and down with a 1-ml syringe and 18-G needle.
31. Load the syringe, change the needle to a 26-G size, and tap to remove bubbles.
32. Inoculate 100 μl of DC suspension subcutaneously into each mouse flank.
Day 14
Lymph node cell preparation 33. Euthanize mice and collect inguinal, axillary, and brachial lymph nodes (Reeves & Reeves, 1992) from both sides in a small volume of RPMI/3% FBS in a 48-well plate, separately for each mouse.
34. Put lymph nodes on a nylon mesh and disaggregate mechanically with the plunger from a 2-ml syringe.
35. Let disaggregated cells pass through the nylon mesh, washing with 5 ml of RPMI containing 3% FBS. Repeat steps 34 and 35 for every lymph node until complete disaggregation is achieved.
36. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
Aspiration of supernatant with a glass Pasteur pipet attached to a vacuum pump minimizes cell loss.
37. Add 10 ml of RPMI/10% FBS to wash pellet.
38. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
39. Resuspend cell pellet in a small volume of RPMI/10% FBS and filter through a nylon mesh into a 12-ml round-bottom tube.
40. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
41. Adjust concentration to 5 × 10 6 cells/ml with RPMI/10% FBS and place cells on ice.
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IDENTIFICATION AND SORTING OF HUMAN M-MDSC CELLS FROM PERIPHERAL BLOOD (PB) OF CANCER PATIENTS TO MEASURE THEIR IMMUNOSUPPRESSIVE ACTIVITY
The aim of this protocol is to obtain CD14 + cells enriched for M-MDSCs from PB of cancer patients, and to preserve their functional activity in order to use them for in vitro functional assays. PBMCs are obtained after centrifugation and sedimentation of whole blood on a Ficoll gradient (see Mandruzzato et al., 2009 ).
The selection of fluorochrome-labeled antibodies to identify M-MDSCs has to be performed based on optimal signal strength and minimal spectral overlap; the optimal concentration of each antibody must be evaluated in titration experiments.
Materials
Anticoagulated whole blood obtained from cancer patients Sorting buffer (see recipe) Human FcR blocking reagent (Miltenyi Biotec) CD14 FITC (clone M5E2, BD Biosciences) HLA-DR APC (clone L243, BD Biosciences) Complete IMDM medium (see recipe)
15-and 50-ml polypropylene conical tubes Refrigerated centrifuge 12 × 75-mm polypropylene tubes pre-coated for at least 1 hr with heat-inactivated fetal bovine serum (FBS) Solito et al.
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Current Protocols in Immunology Additional reagents and equipment for isolating PBMC from whole blood ) and counting viable cells (Strober, 2001) NOTE: All the procedures, including sorting, are performed at 4°C, to avoid cell loss and adherence to the plastic.
Determination of M-MDSCs expression level on PBMCs
The following antibodies were used to characterize blood M-MDSCs in melanoma and meningioma (Pinton et al., 2018) patients: CD14-FITC, HLA-DR-APC and CD124 PE. As the down-regulation of HLA-DR and CD124 expression are important parameters to determine two subsets of M-MDSCs, it is important to use FMO controls to define HLA-DR and CD124 gates as shown in Figure 3 . The protocol for PB-M MDSC staining is described below:
Flow cytometry analysis of PB M-MDSCs
An example of gating strategy, analyzed with FlowJo 7.6.5 software, is shown in Figure 3 . The expression of HLA-DR and CD124 markers is evaluated on CD14 + whole monocytes cells gated on singlet cells and on the basis of FMO signal.
Separation of PB M-MDSCs
6. Stain whole PBMCs (isolated from blood of cancer patients; see step 1) with anti-CD14 and anti-HLA-DR antibodies using the same staining protocol described above. Specifically, for FACS analysis, cells are stained in 12 × 75-mm polypropylene tubes pre-coated for at least 1 hr with heat-inactivated fetal bovine serum (FBS).
7. After labeling, filter cells through a 100-µm cell strainer and isolate CD14 + /HLA-DR low cells by FACS sorting.
Sorting conditions (nozzle, pressure, voltage at the deflection plates, cell rate) should be set up in order to assure maximal monocyte viability after separation. To this purpose, the staining of monocytes with a viability dye 24 and 48 hr after cell sorting is strongly recommended in order to ascertain that a lack in the immunosuppressive activity is real and not influenced by cell death.
8. After the separation, wash and resuspend PB M-MDSCs in 10 ml of complete IMDM. Properly dilute aliquots of the single-cell suspension with trypan blue solution and estimate the number of viable cells (Strober, 2001) .
FACS sorting of CD124 + /CD14 + M-MDSCs is challenging due to low intensity and unimodal expression of CD124. Therefore, in patients with an expansion of CD124 + /CD14 + M-MDSCs, total monocyte fraction can be isolated by immunomagnetic sorting using anti-CD14 microbeads (Miltenyi Biotec) and the manufacturer's protocol. In this case, it would be better to test more than one monocyte: T cell ratio, in order to avoid a lack of immunosuppressive activity due to a high dilution of M-MDSCs in the culture.
BASIC PROTOCOL 8
HUMAN BM-MDSC GENERATION
MDSCs can also be expanded in vitro starting from bone marrow (BM) cell aspirate from healthy donors, as previously described , using the protocol described below. Specifically, we culture BM cells depleted of T, B and NK cells for 4 days with recombinant human (rh) G-CSF and GM-CSF. At the end of the culture, a heterogeneous cell culture is obtained, enriched for BM-MDSCs that are contained in the most immature fraction (Solito et al., 2011b) . To purify BM-MDSCs, the cell culture is depleted of the most mature myeloid cells (CD11b + ) to obtain CD11b low/-BM-MDSCs.
Materials
Bone marrow aspirates (see information in step 1 
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Current Protocols in Immunology Anti-CD3 mAb (optional) Anti-CD19 mAb (optional) Anti-CD56 mAb (optional) 100-μm nylon-mesh cell strainer (BD Biosciences) 15-and 50-ml polypropylene conical tubes Refrigerated centrifuge LD column (Miltenyi Biotec) MACS separator (Miltenyi Biotec) LSRII flow cytometer (BD Biosciences) FlowJo 7.6.5 Software (TreeStar) 24-well tissue culture plate 12 × 75-mm tubes Additional reagents and equipment for counting cells (Strober, 2001) 
Isolation of BM-MDSCs
1. Samples are obtained from BM aspiration both from pediatric patients with normal cytologic characteristics and from adult patients undergoing orthopedic implants. Blood aspirates are collected in tubes containing K 2 EDTA for BM from adults and sodium citrate for pediatric BM. Samples are filtered through a 100-µm cell strainer into 50-ml polypropylene tubes, and red blood cells are removed using a hypotonic solution of ammonium chloride (red blood cell lysis buffer).
The amount of the lysis buffer and the incubation time may be optimized on the basis of BM source. As an alternative source to obtain MDSCs, it is possible to use cultured stem cells (CD34 + cells), which are available from different companies (e.g., AllCell). In our experience, the in vitro differentiation induces the acquisition of immunosuppressive activity and MDSC-associated markers in the cell population that down-regulates the CD34 marker.
2. Wash the cells with complete IMDM. Centrifuge 6 min at 300 × g, 4°C, and discard the supernatant.
3. Resuspend cells in 10 ml of complete IMDM.
5. Incubate 10 7 BM cells in 40 μl of sorting buffer with a mix containing 20 μl of CD3 microbeads, 20 μl of CD19 microbeads, and 20 μl of CD56 microbeads at 4°C for 15 min.
Proportionally scale up the amount of sorting and staining buffer and microbeads on the basis of total number of cells that need to be depleted. For less than 10 7 BM cells keep the same amount of reagents.
6. Wash the cells with sorting buffer, centrifuge 6 min at 300 × g, 4°C, aspirate the supernatant and resuspend the pellet in 500 μl of sorting buffer, then proceed with magnetic separation as described below. For more details, see the protocol from Miltenyi Biotec for magnetic separation with LD columns.
7. Place LD column in the magnetic field of a suitable MACS separator and prepare the column by rinsing it with 2 ml of sorting buffer.
8. Apply cell suspension onto the column; collect unlabeled cells that pass through and wash the column twice with 1 ml of sorting buffer.
9. Wash cells with 10 ml complete IMDM.
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Current Protocols in Immunology 10. Resuspend cells in 10 ml of complete IMDM and dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
11. Take an aliquot of cell suspension and check the enrichment of the myeloid subsets by flow cytometric analysis.
Assess the loss of the lymphocyte region from depleted BM-myeloid cells. The assessment of the morphological features of the depleted samples through flow cytometry may be sufficient for many applications. For transcriptomic analysis, stain depleted myeloid cells with a mixture of antibodies containing anti-CD3/CD19/CD56. For the details of the staining protocol, see Basic Protocol 7.
12. Plate cells (2 × 10 6 cells per well) into a 24-well tissue culture plate in complete IMDM in the presence of rhG-CSF and rhGM-CSF (40 ng/ml) for 4 days, at 37°C with 8% CO 2 .
During this period, it may be useful to observe cells, in order to monitor their growth. Usually it is not necessary to split cultures unless the growth (signaled by medium turning yellow) is excessive. The presence of small areas rich in clusters of myeloid cells with granular aspect indicates that G-CSF/GM-CSF treatment is supporting myeloid survival and proliferation, since this morphology is not present in untreated cultures.
Isolation of CD11b low/-BM-MDSCs
13. After 4 days, harvest cell cultures in 50-ml polypropylene tubes and wash them with complete IMDM. Dilute an aliquot of the single-cell suspension with trypan blue solution, and estimate the number of viable cells (Strober, 2001) .
Usually, the number of viable BM-MDSCs recovered is around 60% of the initial number of plated cells, while recovery of CD11b low/cells is 6% to 7% of total BM-MDSCs after G-CSF/GM-CSF treatment.
14. Incubate 10 7 cells in 80 μl of sorting buffer with 20 μl of CD11b microbeads at 4°C for 15 min.
Scale up the amount of sorting buffer and CD11b microbeads on the basis of total number of cells that need to be depleted. For less than 10 7 BM cells, keep the same amount of reagents.
15. Wash the cells with sorting buffer, centrifuge 6 min at 300 × g, 4°C, aspirate the supernatant, and resuspend the pellet in 500 μl of sorting and straining buffer. Perform magnetic separation as described below. For more details, see the protocol from Miltenyi Biotec for magnetic separation with LD columns.
16. Place LD column in the magnetic field of a suitable MACS separator and prepare the column by rinsing it with 2 ml of sorting buffer.
17. Apply cell suspension onto the column; collect unlabeled cells that pass through and wash the column twice with 1 ml of sorting buffer.
18. Wash cells with complete IMDM.
19. Resuspend cells in 10 ml of complete IMDM and dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
The number of viable cells recovered depends on the cellularity and maturation profile of the BM, but the range is usually between 10 5 and 5 × 10 6 CD11b low/cells.
20. Check the loss of the most mature myeloid cells from the cell culture by flow cytometry (Fig. 4) . Collect cells in 12 × 75-mm tubes for FACS analysis and wash with sorting buffer. Centrifuge 6 min at 300 × g, 4°C, and discard the supernatant.
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Current Protocols in Immunology 21. Incubate the tubes with Fc-receptor blocking reagent diluted 1/25 at 4°C for 10 min. Add the mixture of antibodies (CD11b/CD16) to the tubes and incubate at 4°C for 20 min. Adjust the volume of staining mix to 100 μl with sorting buffer. 22. At the end of the incubation time, wash the cells with sorting buffer. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
23. Resuspend the cells in 250 μl of sorting buffer and perform flow cytometric acquisition and analysis. Figure 4 shows an example of lymphocyte depletion and the gating strategy for CD11b low/-BM-MDSC isolation, analyzed with FlowJo 7.6.5 Software.
Flow cytometry analysis of CD11b low/-BM-MDSCs
BASIC PROTOCOL 9
EVALUATION OF THE SUPPRESSION INDUCED BY HUMAN MDSC ON THE PROLIFERATION OF T CELLS STIMULATED BY ANTI-CD3/ANTI-CD28 AND MEASURED BY CELL TRACE DILUTION
Immune suppression exerted by MDSCs on activated T cells can be measured in terms of inhibition of T cell proliferation. The method can be applied to complex experiments for large-scale screenings, and takes into consideration a basic property of myeloiddependent suppression: the ability to induce proliferative arrest of actively dividing cells.
Materials
Anti-CD3 (0.6 to 5 µg/ml) clone OKT3, obtained after expansion and purification of a commercially available hybridoma Dulbecco's phosphate-buffered saline (DPBS without Ca and Mg; Lonza BioWhittaker, cat. no. BE17-515Q) Complete IMDM medium (see recipe) Immunosuppressive (myeloid) cells, e.g., PB M-MDSCs or CD11b low/-BM-MDSCs (Basic Protocol 7 and 8) 5 µg/ml anti-CD28, clone CD28.2 BioLegend, Catalog #302923) PBMC from healthy donors (see Mandruzzato et al., 2009 , for isolation technique) CellTrace TM Violet Cell Proliferation Kit (Molecular Probes) Solito et al.
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Current Protocols in Immunology Fetal bovine serum (FBS; Gibco or Sigma-Aldrich); FBS used for functional assay should be tested to be sure that immunosuppression is detectable and not overcome by an excessive T cell proliferation Human FcR blocking reagent (Miltenyi Biotec Catalog #130-059-901) Sorting buffer (see recipe) CD3-conjugated to a brilliant fluorochrome (i.e., PC7-anti CD3, clone UCHT1, Catalog # 737657, Beckman Coulter) 24-, 96-, or 384-well flat-bottom microtiter plate 50-ml polypropylene conical tubes (BD Falcon) Refrigerated centrifuge TruCount tubes (Becton Dickinson) LSRII flow cytometer (BD Biosciences) FlowJo 7.6.5 Software (TreeStar)
Additional reagents and equipment to prepare immunosuppressive cells (Basic Protocol 7 and 8), and to count viable cells by trypan blue exclusion (Strober, 2001) Day 0: Culture plate coating 1. Prepare sufficient coating buffer with anti-CD3 (0.6 to 5 μg/ml final concentration in DPBS).
Antibody concentration may be optimized on the basis of stock and supplier.
Usually, we prefer to perform titrations by testing four or five concentrations of anti-CD3 mAb. As an example, it is possible to monitor T cell proliferation by culturing the cells for 4 days in the presence of 5, 2.5, 1.2 and 0.6 μg/ml of anti-CD3. Additionally, it is useful to perform these titration experiments in the presence of suppressive cells, in order to be sure to choose the concentration of anti-CD3 that allows a good proliferation of CD3 + cells and at the same time makes it possible to appraise suppression of T cell proliferation. 
Fill
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7. After counting cells with trypan blue (Strober, 2001) , resuspend them in a suitable volume of 150 μM arginine RPMI containing 10% FBS to adjust cell concentration.
The concentration will depend upon the design of the experiment. A good range of MDSCs is 50% of the total culture cellularity. If 1× 10 5 anti-CD3/CD28 PBMCs are used in a 96-well plate, MDSC concentration can be adjusted to 2× 10 6 /ml, so that 1× 10 5 cells will be plated in 50 μl (50% of total cultured cells). Alternatively, 0.25 × 10 5 anti-CD3/CD28 PBMCs can be used in 384-well plate, and MDSC concentration can be adjusted to 1.25× 10 6 /ml, so that 0.25× 10 5 cells will be plated in 20 μl (50% of total cultured cells).
8. Work in sterility, empty the 96-well microtiter plate or 384-well microplate (from step 5) by inverting it with a rapid movement.
9. Immediately plate suppressive cells in triplicate or duplicate for specific and background proliferation in 50 μl/well (96-well plate) or 20 μl/well (384-well plate), and place the microtiter plate in a 37°C, 5% CO 2 incubator.
When organizing the distribution of samples, avoid using the outer wells, because these wells are more susceptible to evaporation. Outer wells can be filled with sterile DPBS or medium. Remember to fill at least three wells with 10% medium without suppressive cells; these wells will be used as control cultures for the determination of background proliferation. Multiply these control wells for the different treatments according to the experimental setup, e.g., different inhibitors and drugs to be tested.
Prepare responder PBMCs 10. Thaw PBMCs of healthy donors in complete IMDM medium, under sterile conditions and dilute an aliquot of suspension in trypan blue solution, and determine viable cell concentration (Strober, 2001) .
11. Adjust the concentration of PBMCs to 2 × 10 7 cells/ml in DPBS and the concentration of CellTrace to 2× in DPBS; quickly mix equal volumes of PBMCs and CellTrace and incubate for 5 min at 37°C. Add 1/5 of the total volume of FBS, centrifuge 6 min at 300 ×g, 4°C, and plate stained PBMCs at a concentration of 3× 10 6 cells/well in a 24-well plate with complete IMDM medium containing 10% FBS.
The concentration of CellTrace depends on the stock of the reagent and the sensitivity of cells used for the staining, and the reagent should be titrated upon arrival. Usually a range of 0.5 to 2 μM is used.
12. Incubate CellTrace + PBMCs for at least 1 hr in incubator at 37°C, and check the incorporation by flow cytometry. 13. Harvest PBMCs, count them (Strober, 2001) , adjust their concentration at 2 × 10 6 cells/ml for a 96-well plate or 1.25× 10 6 cells/ml for a 384-well plate in 150 μM arginine RPMI containing 10% FBS. Plate them in triplicate or duplicate for specific and background proliferation in 100 μl/well (96-well plate) or 20 μl/well (384-well plate).
Pay attention to the cell distribution scheme. PBMCs will proliferate upon anti-CD3/anti-CD28 stimulation, and their proliferation will be inhibited by immunosuppressive cells; therefore, PBMCs should be distributed in previously anti-CD3-coated wells, either with Solito et al.
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Current Protocols in Immunology or without immunosuppressive cells, as test and reference wells, respectively. Reference wells will contain 1× 10 5 17. Stain cells with anti-CD3 (see Table 2 ) for 20 min at 4°C; in addition, anti-CD4 and CD8 can be added to antibody mix together with anti-CD3 mAb in the same tube, in order to analyze immunosuppression among CD4 and CD8 subsets. Adjust the volume of staining mix to 100 μl with sorting and staining Buffer.
The optimal concentration of CD3, CD4, and CD8 must be evaluated in titration experiments, by analyzing the positive and negative signal of the antibody staining after using seven different concentrations (starting from twice the concentration recommended by the datasheet, dilute 1:2 six times). Remember to include appropriate single-staining controls. The use of anti-CD3 conjugated to a brilliant fluorochrome is recommended in order to clearly distinguish proliferating T cells (that have diluted CellTrace signal) from CellTrace-negative myeloid cells that often present an autofluorescence higher than that of T cells.
18. Wash samples once with sorting and staining buffer, centrifuge the suspension for 6 min at 300 ×g, 4°C, and discard the supernatant.
19. Resuspend samples in 250 μl DPBS, transfer the mix in TruCount tubes, gently vortex them, and proceed with flow cytometric acquisition and analysis.
Flow cytometry analysis 20. Perform flow cytometry acquisition and analysis.
To detect CD3 + proliferating T cells, gate cells first by morphology, and then collect a sufficient number of events in the CD3 + /CellTrace + gate. After the acquisition, proceed with data analysis. Gate cells on morphology and identify CD3 + CellTrace + population. Inside this gate, set a baseline gate on the histograms of CellTrace signal of unstimulated PBMC control, and copy this gate to the stimulated PBMCs cultured in the presence or absence of M-MDSCs, in order to determine the percentage of proliferating T lymphocytes. With FlowJo software, it is possible to model proliferation data; FlowJo presents a graphical display as well as information about each generation in the subset. The proliferation platform also provides information about the fraction of cells from the original population that have divided, and the number of times these cells have divided. In addition, the FlowJo Proliferation Platform draws gates that separate each generation.
21. Proliferation of T cells is evaluated by assessing the signal of CellTrace on CD3 + cells, and considering as proliferating the cells present from generation G2 onwards (see Fig. 5 panel A) , or calculating the absolute number of CD3 + cells in each sample using TruCount tubes. In both cases, data are normalized assuming the proliferation of T cells cultured alone as 100%.
Current Protocols in Immunology Representative examples of two different ways to evaluate immunosuppression. The left plot of panel (A) represents the overlay between CellTrace profile of activated T cells (a-T cells) cultured alone (black peak) or in the presence of MDSCs (white peak). This graph allows to appreciate the increase in the number of undivided cells (higher CellTrace fluorescence) in the presence of MDSCs as compared to T cells alone. This type of immunosuppression was defined as "qualitative" and is quantified by FlowJo proliferation tool, considering as "proliferating" the T lymphocytes belonging to generation G2 onwards and comparing these percentages in the absence (middle plot) or in the presence (right plot) of MDSCs. The histogram in panel (B) instead shows the reduced number of CD3 + T cells quantified by TruCount tubes when activated T cells are cultured in the presence of MDSCs. This type of immunosuppression is defined as "quantitative."
REAGENTS AND SOLUTIONS
μM arginine RPMI containing 10% FBS
Arginine-free RPMI (Biological Industries, Kibbutz Beit Haemek, Israel), supplemented with: 150 μM arginine 10% FBS 10 U/ml penicillin and streptomycin 0.01 M HEPES Store up to 3 days at 4°C 
Complete IMDM medium
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We present three methods to evaluate, either in vitro or in vivo, immune suppression by myeloid cells isolated from mice to the detriment of CD8 + T lymphocytes. The proliferation assay using flow cytometry can be easily performed in many laboratories, in particular to evaluate the proliferation in response to antigen-specific stimuli. Proliferation assays by [ 3 H]TdR incorporation represent a very simple and robust method to quantitatively evaluate the suppressive activity on T cells effected by a nonspecific stimulus (anti-CD3 and anti-CD28 mAbs) to compare many different treatments. On the other hand, these assays can be easily modified to assess alloantigen stimulation ; also see previous version of this unit; doi: 10.1002/0471142735.im1417s91).
Basic Protocol 1, with its simplicity, could be useful to assess large numbers of experimental conditions, such as large screenings of new drugs, or when limited amounts of cells, as in the case of rare populations, are available. It must be pointed out, however, that it only provides information about T cell proliferation but is completely blind to the lymphocyte effector function.
Microcultures with myeloid suppressors, followed by evaluation of cytolytic activity by 51 Cr release, offer the possibility to investigate T cell-specific effector function and its modulation/inhibition by immunomodulatory cells, both preserving the simplicity of proliferation assay and allowing the investigator to work with numerous variables and rare cell populations, which could be difficult to establish under complex in vivo conditions. The chromium release assay is even more laborious than the [ 3 H]TdR uptake assay, but offers a more specific and extended readout. Lytic unit transformation, which measures the extent of suppression normalized to the internal control without suppressive cells, provides a more straightforward representation of the results and allows the comparison and averaging of results from different experiments. Evaluation of L.U. represents a more effective measure than either the proliferation assay or single effector-to-target ratio cytotoxicity value, since it includes an estimation of both functional activity (cytolytic activity of cultures) and cell proliferation (number of cells recovered in each culture). Basic Protocol 6 makes it possible to study tolerogenic activity of immunosuppressive populations in vivo. It could be demanding in terms of time and cost, since it requires a consistent number of immunosuppressive cells per mouse and only allows the investigator to process a few experimental conditions within a single experiment. Flow cytometric evaluation of the expression of both CD8 and CD45.1 markers in the context of a CD45.2 + recipient mouse makes it possible to carefully estimate the relative abundance of transferred T cells within the total CD8 + T cell number in the sample; this assessment could provide information about elimination and/or proliferative blockade of the antigen-specific CD8 + T cells promoted by the immunosuppressive mouse environment. The percentage of CD8 + /CD45.1 + cells could also be used to calculate the total amount of CD8 + /CD45.1 + cells per recipient mouse, taking into account the total number of cells obtained from explanted lymph nodes. Moreover, intracellular staining of IFN-γ will provide a measurement of the activation state of transferred effector cells.
It is not clear whether MDSCs isolated from tumor-free naïve mice are immunosuppressive (Bronte, 2009; Greifenberg et al., 2009; Ribechini, Leenen, & Lutz, 2009 ). It appears that the assay used might influence the extent of suppression. The use of artificially high numbers of MDSC subsets in vitro might unveil inhibitory properties that are intrinsic to these subpopulations, but which will not be manifest in vivo. In particular, a strong activation of effector T cells (such as that induced by antibodies or alloantigens) might also trigger inhibitory pathways in naïve myeloid cells. In this sense, the proliferation assay reported here tends to overestimate the immunosuppressive strength. In our experience, the in vitro parameter that better correlates with the immunosuppressive activity of in vivo-transferred myeloid cells is the capability of these cells to inhibit the effector function of antigen-specific T cells in microcultures when added at low percentages (1% to 6% of total cells in culture), as previously described .
We have discussed protocols for both in vitro and in vivo assays based on the use of specific TCR transgenic CD8 + T cells, but it is clear that these protocols can be adapted to other combinations of TCRs and mouse backgrounds, provided that preliminary experiments are performed to establish the amount of DCs necessary to induce priming of transferred CD8 + T cells. Moreover, in the assays described here, we primarily used naïve CD8 + T cells, but memory/effector T cells could be Solito et al.
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Current Protocols in Immunology isolated from previously primed mice or easily obtained by a previous, short-term stimulation of naïve CD8 + T cells with the antigenic peptide in the absence of myeloid suppressors. Basic Protocols 7, 8 and 9 describe procedures to identify the expansion of human monocytic MDSCs and isolate them from the peripheral blood of cancer patients, as well as to expand CD11b low/-BM-MDSCs in vitro and purify MDSCs in order to evaluate their suppressive function, a mandatory property to define myeloid subsets as MDSCs . In some cases, these myeloid populations can increase in response to tumorderived factors released in the tumor microenvironment, and the opportunity to monitor their level in whole blood through flow cytometry might contribute to give them a prognostic value. Flow cytometry analysis of PBisolated M-MDSCs is rapid and requires a small amount of cells, thus allowing preservation of all the material obtained from whole blood for cell separation and suppression assay.
Critical Parameters and Troubleshooting
For the reasons discussed in Background Information, the most important parameter to consider in evaluating the suppressive activity of myeloid cells is the amount of cells required to give a complete inhibition of the in vitro assay. Although this principle applies to the in vivo assay, technical limitations might preclude in vivo titration as well.
It is of capital importance to make use of excellent-quality FBS in all cultures; in our experience, sera need to be relatively low in growth factors, since their abundance could interfere with suppressive activity by myeloid cells by simply activating/differentiating MD-SCs. It is our practice to screen different lots of FBS to ensure that they do not interfere with the suppressive assay. Briefly, we compare the new FBS batches with the one currently in use in the lab by setting up the suppressive assays described in Basic Protocols 3 and 5 for mouse cells and Basic Protocol 9 for human cells. We select the FBS batch used for cultures whose suppressive activity was similar to those containing the previous FBS. Also, attention should be given to the red cell lysis step, since it has been reported that hemoglobin can scavenge nitric oxide (Azarov et al., 2005) , altering suppressive phenomena that rely on NOS2 and ARG1 activity. Some articles report immunosuppressive assays in which T cell proliferation is ob-tained using beads coated with anti-CD3 and anti-CD28 antibodies. This stimulation needs to be carefully considered, because it has been recently demonstrated that it could lead to artifactual T lymphocyte suppression due to sequestration of beads and their phagocytosis by MDSCs (Davis, Silvin, & Allen, 2017) .
Cell density is a critical parameter for microcultures; thus, particular attention should be paid to cell counts, dilutions, and plating. It is useful to check the percentage of CD8 + T cells that are positive for V α 2 V β 5.1/5.2 in transgenic OT-1 total spleen, and adjust the dilution rate of OT-1 cells to feeder C57Bl/6 cells, in order to obtain the proper state of activation after 5 days of culture.
Latent immunosuppressive programs might be artificially activated either by sorting procedures or in vitro manipulation, a possibility that must be considered for all separating procedures based on antibodies binding to surface molecules. Relevant changes in the amount of either mAbs or beads used for cell sorting of MDSCs should thus be tested accurately, especially in view of the demonstration that some antibodies such as anti-Gr-1 mAb can trigger a signaling cascade in target cells .
Critical parameters in in vivo experiments are usually the number of transferred cells and the proper preparation/maturation of DCs. Moreover, the quality of transferred cells requires attention; sometimes, these cells are very sticky and tend to form clumps, and i.v. inoculation of clumped cells might compromise recipient mouse survival. Maintaining cells on ice during i.v. inoculation prevents clump formation; clumps could also be disaggregated with gentle pipetting, carefully avoiding damage to cells with small-gauge needles.
Antigen specificity is another issue related to the very same biology of suppressor cells that, as with other cellular inhibitors of immune responses, seems to act through both antigen-specific and nonspecific mechanisms (Solito, Bronte, & Mandruzzato, 2011a) . We and others favor the idea that the immunesuppressive mechanisms of MDSCs do not require direct presentation of the antigen, even though this might be a rate-limiting step under some experimental conditions where the encounter with rare CD8 + T cells in lymph nodes might be favored by direct antigen presentation. Although the immune-suppressive mechanisms are mostly antigen-independent, antigen activation is mandatory since MDSCs do not affect resting T cells. The protocols described here can be adapted to evaluate Solito et al.
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It is interesting to note that proliferation/suppression can be evaluated by quantifying the absolute T cell number, and/or by CellTrace profile. In fact, over the years, we have observed, in mouse and human experiments, that in some cases suppression appears as a reduction in the absolute number of T cells (quantitative suppression) and sometimes as a delay in the CellTrace profile (qualitative suppression). Sometimes MDSCmediated immune suppression is both qualitative and quantitative, but in many cases, it is one or another (see Fig. 5 ). Therefore, it would be better to routinely use CellTrace-based proliferation together with the count of absolute numbers of T cells with a standard procedure based on TruCount tube, thus ensuring the possibility of evaluating both. All these considerations suggest that would be important to standardize the conditions for MDSC phenotyping and suppression within and across laboratories in order to define minimal essential criteria enabling reproducible results.
Anticipated Results
The advent of multi-parameter flow cytometry has greatly enhanced the possibility to better characterize the expanded and infiltrating myeloid subsets in cancer models and patients. Moreover, the chance to isolate highly purified immune suppressive subsets by FACS sorting, in addition to immunomagnetic methods, gives us the opportunity to facilitate downstream studies, for example through the characterization of their transcriptome to define molecular targets. Immunosuppressive assays based on CellTrace dilution evaluated by FACS methods are technically very accurate and can be easily reproduced in different laboratories.
[ 3 H]Thymidine incorporation in a 96-well plate usually produces a readout of about 150-200 × 10 3 cpm, while the negative controls fall on the order of 1/100 of the stimulated cells. A properly developed control microculture could induce the lysis of about 70% to 90% of target cells. Usually, the first and second dilution of the culture will be at plateau, and the lysis curve should reach half of the plateau at about fourth-fifths dilution, achieving the baseline at the seventh dilution. Nonspecific lysis should be <30% in the first dilutions and rapidly reach background at the third dilution. Nonspecific lysis may be proportional to specific lysis, and instead of subtracting background from specific lysis, it could be a better approach to minimize nonspecific lysis utilizing a different target cell line that is less sensitive to NK activity. If lytic unit representation is chosen, it could also be informative to take a look at the line plot for each sample, in order to assure proper regression of the results and the consistency of estimated L.U.
A proper immunization with DCs will result in the accumulation of CD8 + /CD45.1 + cells to represent ß2% to 6% of total lymph node cellularity. More than ß60% of CD8 + /CD45.1 + -gated cells should be positive for IFN-γ staining. The samples that have not received ex vivo peptide stimulation usually do not give high background staining compared to matched isotype control.
Time Considerations
The protocols presented here are quite time consuming, and they also require incubations lasting several days. The presented strategy for mouse MDSC enrichment takes ß3 hr to be completed, while the strategy for human M-MDSCs isolation from peripheral blood takes ß5 hr. CellTrace proliferation assays, [ 3 H]TdR proliferation assay, and the 51 Cr release test setup can be completed in at a couple of hours for simple experiments, but could take longer depending on the number of different conditions that need to be tested. [ 3 H]TdR readout could be completed in less than 1 hr, taking into account the quenching period, while the CellTrace proliferation assay takes ß2 hr. Chromium release can be more time consuming, since target cell pulsing usually needs ß1.5 hr to complete pulsing, washing, and cell counting. Dilution of CTL cultures could be performed during target pulsing, and, usually, the setup of a commonly sized experiment with 15 to 20 different experimental conditions in triplicate could be completed within the time of pulsing. After 5 hr of effector/target co-culture, the supernatant transfer could take at least 30 min. LumaPlates need to be read the following day.
In vivo experiments are quite demanding; challenging steps usually include the achievement of a suitable amount of suppressive cells, which could take several hours of sorting, and the single-recipient processing of lymph nodes, which could take about 6 hr for a simple experiment with about 20 recipients. Flow cytometric acquisition could also take a long time, depending on the Solito et al.
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Recently, it has emerged that the immunosuppressive mechanisms mediated by MDSCs could be different for different tumors. In the future, it may be necessary to reevaluate the technical measures to optimize the isolation of MDSCs and standardize the appropriate functional tests by comparing the districts where these cells are present and different tumor types (Damuzzo et al., 2015; Kumar, Patel, Tcyganov, & Gabrilovich, 2016) .
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